BIO-Europe 2026: Envisagenics is harnessing RNA splicing as its therapeutic approach - which may open up biology to novel targets
Co-Founder & CEO Maria Pineda describes the idea behind RNA splicing, which the company is using initially against (currently unnamed) CNS and oncology targets. It also recently announced a multi-target collaboration with Boehringer Ingelheim for oncology.
Coverage brought to you by










.png)
